Conventional cytotoxic cancer chemotherapy is often immunosuppressive and associated
with drug resistance and tumor regrowth after a short period of tumor shrinkage or growth …

In addition to the contribution of cancer cells, the solid tumor microenvironment (TME) has a
critical role in determining tumor expansion, antitumor immunity, and the response to …

Cimetidine, the first H 2 receptor antagonist in widespread clinical use, has anti-cancer
properties that have been elucidated in a broad range of pre-clinical and clinical studies for …

The administration of chemotherapy at reduced doses given at regular, frequent time
intervals, termed 'metronomic'chemotherapy, presents an alternative to standard maximal …

Each year more than 65,000 people are diagnosed with urinary bladder cancer, and more
than 14,000 people die from the disease in the United States. Studies in relevant animal …

Anticancer treatment efficacy is limited by the development of refractory tumor cells
characterized by increased expression and activity of mechanisms promoting survival …

Simple Summary The present article reviews the state of the art of metronomic
chemotherapy use to treat the principal types of cancers, namely breast, non-small cell lung …

Metronomic chemotherapy, continuous and dose‐dense administration of chemotherapeutic
drugs with lowered doses, is being evaluated for substituting, augmenting, or appending …

Cancer-related death is a significant health and economic burden worldwide, and some
conventional chemotherapy is associated with limited effectiveness in completely curing …

Diclofenac (DCF) is a well-known and widely used non-steroidal anti-inflammatory drug
(NSAID), with a range of actions which are of interest in an oncological context. While there …